Post Market Clinical Follow-Up KeriFuse®

Effectiveness and Safety of the KeriFuse® Intramedullary Arthrodesis Implant and Associated Instruments in the Treatment of IP or DIP Arthritis: a Post Market Clinical Follow-up.

The general objective of this study is to evaluate the performances and the safety related to the KeriFuse® intramedullary arthrodesis implant and associated instrumentation used in accordance with their approved labelling and instruction for use. Performance and safety of KeriFuse® intramedullary arthrodesis implant will be established on short and middle-terms in regards to the implant life-cycle.

Inclusion Criteria:

• Patients ≥ 18 years,
• Patients that will have a surgery using a KeriFuse® implant in accordance with the approved labelling and IFU.

Exclusion Criteria:

• Pregnant or nursing women,
• Patients with intellectual disabilities who cannot follow the instructions of their surgeon,
• Patients with a contraindication to surgery and more specifically to the implantation of KeriFuse®,
• Patients with acute or chronic infections, local or systemic,
• Patients with sensitivities or allergies to the implant components (Nickel, Titanium).